Assessing Fixed|Duration Obinutuzumab

Fixed-duration venetoclax plus obinutuzumab improves quality of ...

To assess the impact of geriatric assessment on treatment outcomes and the patients' HRQoL, patient-reported outcomes (PROs), including ...

Assessing Fixed-Duration Obinutuzumab, Ibrutinib, and Venetoclax ...

She also shares her thoughts on what the future holds for combination therapy in the treatment of chronic lymphocytic leukemia (CLL). Please ...

Fixed-duration venetoclax plus obinutuzumab improves quality of ...

To assess the impact of geriatric assessment on treatment outcomes and the patients' HRQoL, patient-reported outcomes (PROs), including function ...

CLL14 Long-Term Results of Fixed-Duration Venetoclax Plus ...

CLL14: Long-Term Results of Fixed-Duration Venetoclax Plus Obinutuzumab in Elderly Patients With CLL ... evaluate the efficacy and safety ...

Venetoclax consolidation after fixed-duration ... - The Lancet

... obinutuzumab”, with no language restrictions. We found that the combination of venetoclax and obinutuzumab has been assessed in phase 1, 2, and 3 studies ...

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ...

Methods: In this open-label, phase 3 trial, we investigated fixed-duration ... The primary end point was investigator-assessed progression ...

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ...

To evaluate whether venetoclax–obinutuzumab is superior to ... fixed-duration, noncytotoxic regimen, venetoclax–obinutuzumab. The ...

Fixed-Duration Regimen Safe, Effective for CLL | ASH Clinical News

... fixed-duration treatment with venetoclax-obinutuzumab (Ven-Obi) experience sustained long-term survival, undetectable measurable residual ...

Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on ...

7502Background: The multinational, open-label, phase 3 CLL14 trial compared fixed-duration targeted VenG treatment with ...

Fixed-duration venetoclax plus obinutuzumab improves quality of ...

To assess the impact of geriatric assessment on treatment outcomes and the patients' HRQoL, patient-reported outcomes (PROs), including function ...

Expert Perspectives on Fixed Duration Therapy with Venetoclax + ...

A panel of experts discuss the role of fixed duration therapy with venetoclax and obinutuzumab, outlining their general approach for patient ...

Durable efficacy with fixed‐duration BTKi and venetoclax for CLL

A fixed-duration combination regimen of obinutuzumab, ibrutinib, and ... The study is the first to assess IVO for CLL and included 75 patients ...

7-year update on a Phase II trial of fixed-duration obinutuzumab ...

7-year update on a Phase II trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL. 273 views · 4 months ago ...more ...

Fixed-Duration Venetoclax plus Obinutuzumab New Standard of ...

In the phase 3 CLL14 clinical trial, fixed-duration venetoclax plus obinutuzumab was superior to chlorambucil plus obinutuzumab as front-line therapy in ...

Fixed-duration Calquence plus venetoclax, with or without ...

The OS data were not mature at the time of this analysis and the trial will continue to assess ... obinutuzumab for a fixed duration or standard- ...

Fixed-duration venetoclax-obinutuzumab for previously untreated ...

Assessment of minimal residual disease 18 months after end of treatment showed that 47.2% of patients in the VenG arm had undetectable (u) uMRD ...

Evaluating Maintenance Therapy After Fixed-Duration ...

Evaluating Maintenance Therapy After Fixed-Duration Obinutuzumab Plus Venetoclax in CLL - Chronic Leukemias, On Location, Other Meetings ...

A phase 2 study of fixed duration therapy with pirtobrutinib and ...

This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of ...

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic ...

This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as ...

Dr. Al-Sawaf on the Benefit of Fixed-Duration Obinutuzumab ...

Nicole Lamanna, MD, highlights various clinical trials underway evaluating new treatment options for patients with chronic lymphocytic leukemia.